Side-by-side · Research reference
SNAP-8vsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED8/46 cited
BPhase 3HUMAN-REVIEWED25/54 cited
SNAP-8
Synthetic Octapeptide · Cosmetic Topical
TopicalRoute
8-AAPeptide length
SNAREPrimary target
Topical · Facial application · Twice daily
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
SNAP-8
Survodutide
Primary target
SNARE complex (SNAP-25 competitive binding site)
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
N/A — topical cosmetic, no systemic endocrine axis
—
Origin
Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)
—
Antibody development
—
—
02Dosage Protocols
Parameter
SNAP-8
Survodutide
Typical concentration
2–10% in cosmetic formulationsLupin 2024Raikou 2017
Commercial products typically use 5–10%.
—
Treatment duration
20–60 days for visible effectRaikou 2017
Skin microtopography improvements measured at 20-day intervals.
—
Formulation type
Oil-in-water emulsion, serum, cream
—
Application site
Facial skin — glabellar lines, crow's feet, forehead
—
Evidence basis
RCT, in vitro skin penetration studies
Phase 2 RCT (obesity) · Phase 3 ongoing
Frequency
—
Once weekly
03Metabolic / Fat Loss Evidence
Parameter
SNAP-8
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
SNAP-8
Survodutide
Cytotoxicity
Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)
Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.
—
Skin irritation
Minimal; well-tolerated in clinical use
—
Peptide oxidation
Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021
Formulation stability issue, not a direct adverse effect.
—
Hypersensitivity
Rare; no widespread allergic reactions reported
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
SNAP-8
- ·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
SNAP-8
- ·Active skin infections or open wounds at application site
- ·Neuromuscular disorders (theoretical concern, no documented cases)
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
SNAP-8
Survodutide
1. Cleansing
Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Application
Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Frequency
Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Layering
Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Storage
Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
6. Duration
Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.
—